CENTENNIAL, Colo., June 1, 2006 -Cell>Point today announced it plans to start a Phase II clinical trial to evaluate the effectiveness of its 99mTc-EC-DG (Technetium-99m-Ethylenedicys-teine-Deoxyglucose) in diagnosing the presence of viable tissue in regions of the myocardium damaged by myocardial infarction or chronic coronary artery disease.
The company has completed the Phase I safety trial on 99mTc-EC-DG in addition to canine heart remodeling studies.
Previously developed as a functional imaging agent for oncology applications, 99m Tc-EC-DG should improve diagnostic accuracy in determining if a patient would benefit from coronary revascularization, Cell>Point believes, whether in the setting of the cardiologist’s practice or hospital emergency room. The sooner the diagnosis is confirmed, the better chance a patient will have for improved systolic function following a myocardial infarction.
In addition to myocardial viability, Cell>Point plans to study the effectiveness of 99mTc-EC-DG in other cardiac indications including a study in conjunction with myocardial perfusion imaging in women (who often exhibit false-positive results following the perfusion stress procedure), and a study of early diagnosis of congestive heart failure onset.